Longitudinal tracking of FTLD: Toward developing clinical trial methodology

David S. Knopman; Bradley S. Boeve; Richard J. Caselli; Neill R. Graff-Radford; Joel H. Kramer; Mario F. Mendez; Bruce L. Miller

doi:10.1097/WAD.0b013e31815bf69d

Longitudinal tracking of FTLD: Toward developing clinical trial methodology

David S. Knopman, Bradley S. Boeve, Richard J. Caselli, Neill R. Graff-Radford, Joel H. Kramer, Mario F. Mendez, Bruce L. Miller

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

Original language	English (US)
Pages (from-to)	S58-S63
Journal	Alzheimer disease and associated disorders
Volume	21
Issue number	4
DOIs	https://doi.org/10.1097/WAD.0b013e31815bf69d
State	Published - Oct 2007

Keywords

Clinical trials
Frontotemporal lobar degeneration
Longitudinal studies
Primary progressive aphasia

ASJC Scopus subject areas

Clinical Psychology
Gerontology
Geriatrics and Gerontology
Psychiatry and Mental health

Access to Document

10.1097/WAD.0b013e31815bf69d

Cite this

@article{48a856178d9d42259b34bdd256a399b6,

title = "Longitudinal tracking of FTLD: Toward developing clinical trial methodology",

abstract = "Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.",

keywords = "Clinical trials, Frontotemporal lobar degeneration, Longitudinal studies, Primary progressive aphasia",

author = "Knopman, {David S.} and Boeve, {Bradley S.} and Caselli, {Richard J.} and Graff-Radford, {Neill R.} and Kramer, {Joel H.} and Mendez, {Mario F.} and Miller, {Bruce L.}",

year = "2007",

month = oct,

doi = "10.1097/WAD.0b013e31815bf69d",

language = "English (US)",

volume = "21",

pages = "S58--S63",

journal = "Alzheimer disease and associated disorders",

issn = "0893-0341",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Longitudinal tracking of FTLD

T2 - Toward developing clinical trial methodology

AU - Knopman, David S.

AU - Boeve, Bradley S.

AU - Caselli, Richard J.

AU - Graff-Radford, Neill R.

AU - Kramer, Joel H.

AU - Mendez, Mario F.

AU - Miller, Bruce L.

PY - 2007/10

Y1 - 2007/10

N2 - Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

AB - Putative treatments for the frontotemporal lobar degenerations are likely to become available for testing in clinical trials in the next few years. To design clinical trials for this group of disorders, a number of conceptual, methodologic, and diagnostic issues must be resolved. This presentation reviews diagnostic criteria, instruments for longitudinal study, questions about study duration, and the possible uses of biomarkers in clinical trials. In addition, a multicenter trial is described in which some aspects of diagnosis and longitudinal measurement in the frontotemporal lobar degenerations are being specifically explored.

KW - Clinical trials

KW - Frontotemporal lobar degeneration

KW - Longitudinal studies

KW - Primary progressive aphasia

UR - http://www.scopus.com/inward/record.url?scp=37349126255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349126255&partnerID=8YFLogxK

U2 - 10.1097/WAD.0b013e31815bf69d

DO - 10.1097/WAD.0b013e31815bf69d

M3 - Article

C2 - 18090426

AN - SCOPUS:37349126255

SN - 0893-0341

VL - 21

SP - S58-S63

JO - Alzheimer disease and associated disorders

JF - Alzheimer disease and associated disorders

IS - 4

ER -

Longitudinal tracking of FTLD: Toward developing clinical trial methodology

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this